Stock Events

Arvinas 

$24.4
24
-$0.55-2.2% Friday 20:00

Statistics

Day High
25.17
Day Low
23.75
52W High
53.08
52W Low
13.57
Volume
390,489
Avg. Volume
800,541
Mkt Cap
1.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

5
NOV
Earnings
 

Earnings

5NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-2.53
-1.85
-1.17
-0.49
Expected EPS
-0.946584
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARVN. It's not an investment recommendation.
Alphabet
72554
GOOGL
Apple
63389
AAPL
Microsoft
59081
MSFT
Amazon
54705
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap179.38B
Amgen is a biotechnology company that competes with Arvinas in the development of novel therapeutics for cancer and other serious diseases.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Arvinas, particularly in oncology.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb competes with Arvinas in the oncology sector, focusing on developing cancer treatments including protein degradation therapies.
Novartis
NVS
Mkt Cap244.75B
Novartis is a global healthcare company that competes with Arvinas in researching and developing innovative medicines, including treatments for cancer.
Merck
MRK
Mkt Cap300.25B
Merck is known for its research-driven pharmaceutical products, competing with Arvinas in the oncology space, particularly in developing cancer therapies.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a research-based biopharmaceutical company that competes with Arvinas in the development of drugs for various diseases, including cancer.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie is involved in the discovery of new medicines, competing with Arvinas in the therapeutic area of oncology, among others.
Roche
RHHBY
Mkt Cap272.83B
Roche Holding AG competes with Arvinas through its strong focus on oncology, developing innovative cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly and Company competes with Arvinas in the pharmaceutical sector, focusing on oncology and other areas of unmet medical need.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals is a biotechnology company that competes with Arvinas in developing innovative treatments for cancer, among other diseases.

Analyst Ratings

62.14$Average Price Target
The highest estimate is $87.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Medicinal and Botanical Manufacturing
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Show more...
CEO
John G. Houston
Employees
445
Country
US
ISIN
US04335A1051

Listings

XNAS
US
ARVN